Nek­tar takes the spot­light at SITC tout­ing some promis­ing ear­ly da­ta for hard-to-treat can­cers

WASH­ING­TON, DC — One of Nek­tar Ther­a­peu­tics’ top can­cer drugs gained the spot­light at the So­ci­ety for Im­munother­a­py of Can­cer meet­ing over the week­end with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER